Dignitana AB Publishes Q4 2023 Interim Report
Positive EBITDA, continued growth and high margin Financial highlights Q4 2023 · Net sales amounted to 22.2 MSEK (18.6), an increase of 19 percent over the same period in 2022. · Operating result amounted to-3.1 MSEK (-3.6). · Net result after financial items amounted to-3.7 MSEK (-3.7). · EBITDA for the Third Quarter is positive at 674 TSEK (-119). · Earnings per share were-0.05 SEK (-0.06). · Cash Balance amounted to 7.0 MSEK (6.7). · Average Daily Treatment Revenue (ADTR)* was 237 TSEK (203), an increase of 17 percent over the same period in 2022 Financial